Ion Beam Applications S.A.
$32.3K 17 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Smaio SA
Smaio SA reported $32,283.91 across General Payments, Research, and Ownership to 70 physicians and teaching hospitals across 70 transactions.
- $32.3K Below-median payer
- All-tracks total
- 70 Below-median volume
- Transactions
- 70 Below-median reach
- Recipients
- −$49.7K
- General Payments vs PY2023
Smaio SA reported $32,283.91 across all CMS Open Payments tracks (General + Research + Ownership) to 70 physicians and teaching hospitals in Program Year 2024 - ranking #1454 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $32,283.91, averaging $461.20 per recipient.
Smaio SA's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
23/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer smaio-sa Smaio SA
$32.3K · #1454/1,925 · 0.0% industry · PY2024
- TOT $32.3K
- RANK #1454
- SHARE 0.0%
- TXN 70
- RCP 70
- CAT 5
- GEN $32.3K
- ΔGEN −$49.7K
- TOP1 29.5%
- PY 2024
Volume peers
Nearest volume peer: Ion Beam Applications S.A. ($32.3K)
Smaio SA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Smaio SA's CMS-reported General Payments decreased by $49.7K (−60.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SMAIO SAPY2023: SMAIO SAPY2024: SMAIO SA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $81,979.89
- PY2024
- $32,283.91
What the Data Shows for Smaio SA
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Smaio SA that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 5 general-payment categories charted below, "Royalty or License" is the largest at $9.5K across 2 transactions, 29.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Smaio SA made 5 types of general payments. "Royalty or License" is the largest category at $9.5K, 29.5% of General Payments.
Smaio SA reports 5 general-payment categories - the top three are Royalty or License (29.5%), Travel and Lodging (26.3%), and Consulting Fee (18.6%). The remaining 2 categories make up 25.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Smaio SA divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $9.5K | 2 | 29.5% |
| Travel and Lodging | $8.5K | 10 | 26.3% |
| Consulting Fee | $6.0K | 2 | 18.6% |
| Food and Beverage | $5.3K | 55 | 16.3% |
| Honoraria | $3.0K | 1 | 9.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $22,897.14 (70.9%) of $32,283.91 in this company's General Payments records across 16 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Smaio SA
The five named recipients with the highest reported General Payments from this company
- 1
Christopher J Dewald
$9,521.89 across 2 reported transactions
- 2
Gregory Michael Mundis
$3,546.17 across 5 reported transactions
- 3
Robert K Eastlack
$3,466.46 across 1 reported transactions
- 4
Munish Chandra Gupta
$3,362.62 across 3 reported transactions
- 5
Han Jo Kim
$3,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Smaio SA ranks #1454 of 1,925 by total payments (bottom 25% by spend) but is notably more concentrated than that alone would suggest -- #878 of 1,838 by HHI (top 48% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Ossur Americas, Inc. : $259.2K total payments, HHI 1476
- Nexus CMF, LLC : $69.0K total payments, HHI 1476
- Vertex Pharmaceuticals Incorporated : $6.9M total payments, HHI 1475
- Theragen, Inc. : $28.8K total payments, HHI 1475
- Ferring Pharmaceuticals AS : $71.5K total payments, HHI 1474
- Dunamis Medical, LLC : $6.0K total payments, HHI 1473
- Smaio SA (this company) : $32.3K total payments, HHI 1470
- Microsurgical Technology, Inc. : $97.7K total payments, HHI 1467
- Janssen Global Services, LLC : $1.8M total payments, HHI 1459
- Sequel Med Tech, LLC : $5.1K total payments, HHI 1455
- United Imaging Healthcare North America LLC : $51.7K total payments, HHI 1453
- Qapel Medical Inc : $256.6K total payments, HHI 1446
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Smaio SA's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Smaio SA.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Smaio SA.
Showing 6 of 1,924 companies with CMS-reported payment data.
Dentsply Sirona KK
$32.4K 13 recipients
Compare payment profiles
Tigon Medical LLC
$32.6K 36 recipients
Compare payment profiles
Electronic Waveform Lab, Inc.
$32.0K 1,902 recipients
Compare payment profiles
Mission Medical Distribution, LLC
$32.7K 344 recipients
Compare payment profiles
McKesson Sourcing Services, Inc.
$32.7K 43 recipients
Compare payment profiles
Put this to use
Smaio SA ranks #1454 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Smaio SA. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.